Kairos Pharma’s (KAPA) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has a $9.00 price target on the stock.

Kairos Pharma Price Performance

Shares of KAPA stock opened at $1.22 on Tuesday. Kairos Pharma has a fifty-two week low of $0.40 and a fifty-two week high of $3.25. The stock’s 50-day moving average is $1.27 and its two-hundred day moving average is $0.94. The firm has a market cap of $25.30 million and a P/E ratio of -3.59.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kairos Pharma stock. XTX Topco Ltd purchased a new position in shares of Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 62,746 shares of the company’s stock, valued at approximately $44,000. XTX Topco Ltd owned approximately 0.31% of Kairos Pharma as of its most recent filing with the SEC.

About Kairos Pharma

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.